Study Clarifies Who Gets Post –COVID-19 Interstitial Lung Disease Study Clarifies Who Gets Post –COVID-19 Interstitial Lung Disease
A study of post –COVID-19 patients in the UK who developed severe lung inflammation after they left the hospital may provide greater clarity on which patients are most likely to have persistent lung dysfunction.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - March 4, 2021 Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news

Tocilizumab May Improve Lung Function in Early Systemic Sclerosis Tocilizumab May Improve Lung Function in Early Systemic Sclerosis
Treatment with tocilizumab could stabilize or improve lung function in people with early interstitial lung disease associated with systemic sclerosis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 19, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Lung Disease Raises Mortality Risk in Older RA Patients Lung Disease Raises Mortality Risk in Older RA Patients
RA-associated interstitial lung disease has been associated with worse survival rates as well as reduced quality of life, functional impairment, and increased health care use and costs.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 28, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

FDA grants priority review to Roche ’s Esbriet (pirfenidone) for unclassifiable interstitial lung disease
Basel, 21 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet® (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD). The FDA is expected to make a decision on approval by May 2021.“Since its US approval, Esbriet has become a standard of care for people living with idiopathic pulmonary fibrosis. However, significant unmet need remains in fibrotic lung diseases, including unclassifiable interstitial lung disease ...
Source: Roche Investor Update - January 21, 2021 Category: Pharmaceuticals Source Type: news

Inhaled Treprostinil Beneficial in Pulmonary Hypertension
Exercise capacity improved, clinical worsening reduced for patients with pulmonary HTN due to interstitial lung disease (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 14, 2021 Category: Respiratory Medicine Tags: Cardiology, Pharmacy, Pulmonology, Journal, Source Type: news

Inhaled Treprostinil Beneficial in Pulmonary Hypertension
THURSDAY, Jan. 14, 2021 -- Inhaled treprostinil improves exercise capacity in patients with pulmonary hypertension due to interstitial lung disease, according to a study published online Jan. 13 in the New England Journal of Medicine. Aaron Waxman,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2021 Category: Pharmaceuticals Source Type: news

CT helps clinicians predict emphysema progression
The pattern of parenchymal emphysema on baseline CT scans forecasts progression...Read more on AuntMinnie.comRelated Reading: Deep-learning algorithm detects free air on CT images Machine learning boosts chest CT's performance CT textures predict interstitial lung disease survival COVID-19 patients face higher risk of barotrauma CT helps predict TAVR outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 18, 2020 Category: Radiology Source Type: news

Study connects diabetes, air pollution to interstitial lung disease
(Michigan State University) People with pre-diabetes or diabetes who live in ozone-polluted areas may have an increased risk for an irreversible disease with a high mortality rate. These findings are especially important today in the midst of the COVID-19 pandemic, where there is a heightened concern for the convergence of health effects from air pollution and SARS-CoV-2 in susceptible populations. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2020 Category: International Medicine & Public Health Source Type: news

Home oxygen therapy for adults with COPD and ILD: New ATS clinical practice guideline
(American Thoracic Society) The latest clinical practice guideline on home oxygen therapy addresses long-term and ambulatory oxygen therapy for adults with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) and includes the most comprehensive review of the evidence of any oxygen guideline to date. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2020 Category: International Medicine & Public Health Source Type: news

Interstitial Lung Disease (Interstitial Pneumonia)
Title: Interstitial Lung Disease (Interstitial Pneumonia)Category: Diseases and ConditionsCreated: 11/10/2014 12:00:00 AMLast Editorial Review: 11/12/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - November 12, 2020 Category: Respiratory Medicine Source Type: news

Interstitial Lung Disease
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - November 12, 2020 Category: General Medicine Source Type: news

Pregnancy Can Be Safe With Interstitial Lung Disease Pregnancy Can Be Safe With Interstitial Lung Disease
Often women with ILD related to an autoimmune disease are advised to avoid conception or terminate their pregnancy. But the largest study to date on the subject draws more optimistic conclusions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 8, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Interstitial lung disease associated with systemic sclerosis large burden
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2020 Category: Drugs & Pharmacology Source Type: news

InPedILD_trial_enrollment
Phase III InPedILD ™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung diseaseFirst-of-its-kind clinical trial in children and adolescents with fibrosing interstitial lung disease (ILD) initiated globallyThis new study builds on the Phase III INBUILD ® trial and approval of Ofev® in adult patients with fibrosing ILDs with a progressive phenotype1,2,3Global Phase III multicentre clinical trial is planned to be conducted in approximately 70 sites in 24 countries (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 12, 2020 Category: Research Source Type: news

Oxidative cross-linking of fibronectin confers protease resistance and inhibits cellular migration
The oxidation of tyrosine residues to generate o,o'-dityrosine cross-links in extracellular proteins is necessary for the proper function of the extracellular matrix (ECM) in various contexts in invertebrates. Tyrosine oxidation is also required for the biosynthesis of thyroid hormone in vertebrates, and there is evidence for oxidative cross-linking reactions occurring in extracellular proteins secreted by myofibroblasts. The ECM protein fibronectin circulates in the blood as a globular protein that dimerizes through disulfide bridges generated by cysteine oxidation. We found that cellular (fibrillar) fibronectin on the su...
Source: Signal Transduction Knowledge Environment - August 10, 2020 Category: Science Authors: Locy, M. L., Rangarajan, S., Yang, S., Johnson, M. R., Bernard, K., Kurundkar, A., Bone, N. B., Zmijewski, J. W., Byun, J., Pennathur, S., Zhou, Y., Thannickal, V. J. Tags: STKE Research Articles Source Type: news

ATS Issues Guide for Diagnosing Hypersensitivity Pneumonitis
Systematic approach developed for diagnosis of nonfibrotic, fibrotic HP in interstitial lung disease (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 5, 2020 Category: Respiratory Medicine Tags: Pathology, Pulmonology, Radiology, Allergy, Journal, Source Type: news

Drug-induced interstitial lung disease in breast cancer patients
(Compuscript Ltd) Drug-induced Interstitial Lung Disease in Breast Cancer Patients: A Lesson We Should Learn from Multi-Disciplinary IntegrationAnnouncing a new article publication for BIO Integration journal. In this case report the authors Zijun Zhao, Zhanghai He, Hongyan Huang, Jiewen Chen, Shishi He, Ailifeire Yilihamu and Yan Nie from Sun Yat-sen University, Guangzhou, China consider drug-induced interstitial lung disease in breast cancer patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 27, 2020 Category: International Medicine & Public Health Source Type: news

CT textures predict interstitial lung disease survival
Quantitative analysis of texture patterns on CT exams in interstitial lung...Read more on AuntMinnie.comRelated Reading: Which smokers seek out CT lung cancer screening? ECR 2020: COVID-19 greatest health threat since Spanish flu Dual-energy CT, CTA reveal COVID-19 lung patterns RSNA's COVID-19 chest CT classification system holds up AI helps distinguish COVID-19 from other pneumonias (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 23, 2020 Category: Radiology Source Type: news

EC_approval_nintedanib_ILD_PF
European Commission approves third nintedanib indication in pulmonary fibrosis1The approval is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1The decision is based on the results of the INBUILD ® trial, the first study to evaluate patients with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behavior.2Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated inters...
Source: Boehringer Ingelheim Corporate News - July 15, 2020 Category: Research Source Type: news

Treprostinil Improves Walk Distance in Pulmonary Hypertension Treprostinil Improves Walk Distance in Pulmonary Hypertension
Exercise capacity increased after patients with pulmonary hypertension associated with interstitial lung disease were treated with the vasodilator for 16 weeks, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 9, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

No Link Between Methotrexate, Interstitial Lung Disease in RA No Link Between Methotrexate, Interstitial Lung Disease in RA
Patients with rheumatoid arthritis are at elevated risk for interstitial lung disease, but methotrexate does not accentuate that risk and may be protective, new data show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

CHMP_opinion_nintedanib_ILD_PF
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis1The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).2The U.S. Food and Drug Administration (FDA) and Health Canada recently approved nintedanib as the first treatment for the same patient population.3,4Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in mo...
Source: Boehringer Ingelheim Corporate News - May 29, 2020 Category: Research Source Type: news

NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease
NICE has published two new rapid COVID-19 guidelines. (Source: NHS Networks)
Source: NHS Networks - May 18, 2020 Category: UK Health Source Type: news

COVID-19 rapid guideline: interstitial lung disease [NG177], NICE
The guideline provides clinicians with advice on how to adjust care to reduce patients'exposure to COVID-19 and how to balance the risks and benefits of taking drugs that affect the immune response during the pandemic. The guideline highlights that bronchoscopy and pulmonary function tests have the potential to spread COVID-19 and they should only be carried out if the patient urgently needs them and if the results will have a direct impact on their care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 18, 2020 Category: Consumer Health News Source Type: news

European_Commission_approves_nintedanibSSc-ILD
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)Approval is based on the SENSCIS ® study which showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD)1Following the FDA ’s approval in September 2019, nintedanib in SSc-ILD has so far been approved in 15 countries including Canada, Japan and BrazilBeing the first and only approved treatment option available for people living with SSc-ILD, the approval constitutes a breakthrough in an area of high unmet need (Source: Boehring...
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news

VIDA Completes Second Close Of Round C Financing
CORALVILLE, Iowa, April 15, 2020 -- (Healthcare Sales & Marketing Network) -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, received $2M from OSF Ventures, the corporate investment arm of OSF HealthCare, as a s... Devices, Venture Capital VIDA Diagnostics, COPD, asthma, interstitial lung disease, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 15, 2020 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease
Basel, 3 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet ® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD[1]. The study represented the first randomised controlled trial to exclusively enroll patients with progressive fibrosing uILD.“Today’s milestone for Esbriet builds on our continued commitment to improving the standard of care ...
Source: Roche Investor Update - March 3, 2020 Category: Pharmaceuticals Source Type: news

CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease  Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults1Based upon positive SENSCIS ® trial results nintedanib was approved as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with SSc-ILD2Nintedanib is already approved in more than 70 countries for the tre...
Source: Boehringer Ingelheim Corporate News - February 28, 2020 Category: Research Source Type: news

High-Res CT Has Key Role Detecting Lung Disease in Systemic Sclerosis High-Res CT Has Key Role Detecting Lung Disease in Systemic Sclerosis
The first evidence-based consensus statements for systemic sclerosis-associated interstitial lung disease (SSc-ILD) recommend use of high-resolution computed tomography (CT) for screening and diagnosis, and offer guidance on when to initiate or escalate emerging treatment options.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 4, 2020 Category: Radiology Tags: Rheumatology News Source Type: news

$20 million fundraising effort will support efforts to improve treatment for lung disease
UCLA Health has launched a $20 million fundraising initiative to create a new center for advanced lung disease at theDavid Geffen School of Medicine at UCLA. To date, the initiative has secured $4.37 million for the Lung Health Research Accelerator Fund, including three gifts of $1 million each from Michael and Linda Keston, William Pierpoint, and Jeffrey and Robin Raich, and a total of $1.37 million from nine other donors.The fund will support the work of Dr. John Belperio and Dr. Joseph Lynch III in the medical school ’s division of pulmonary and critical care medicine. Belperio’s research is focused on ident...
Source: UCLA Newsroom: Health Sciences - November 15, 2019 Category: Universities & Medical Training Source Type: news

$20 million fundraising initiative will support efforts to improve treatment for lung disease
UCLA Health has launched a $20 million fundraising initiative to create a new center for advanced lung disease at theDavid Geffen School of Medicine at UCLA. To date, the initiative has secured $4.37 million for the Lung Health Research Accelerator Fund, including three gifts of $1 million each from Michael and Linda Keston, William Pierpoint, and Jeffrey and Robin Raich, and a total of $1.37 million from nine other donors.The fund will support the work of Dr. John Belperio and Dr. Joseph Lynch III in the medical school ’s division of pulmonary and critical care medicine. Belperio’s research is focused on ident...
Source: UCLA Newsroom: Health Sciences - November 15, 2019 Category: Universities & Medical Training Source Type: news

FDA Grants Ofev(R) Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
The designation was supported by results from the Phase III INBUILD® study that met its primary endpoint and was recently published in the New England Journal of Medicine RIDGEFIELD, Conn., Oct. 10, 2019 -- (Healthcare Sales & Marketing Network) --... Biopharmaceuticals, FDA Boehringer Ingelheim, Ofev, nintedanib, interstitial lung disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 10, 2019 Category: Pharmaceuticals Source Type: news

VIDA Expands Board, Announcing Erkan Akyuz As Independent Director
CORALVILLE, Iowa, Oct. 4, 2019 -- (Healthcare Sales & Marketing Network) -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, today announced the appointment of Erkan Akyuz as independent director. Mr. Akyuz will j... Devices, Radiology, Oncology, Personnel VIDA Diagnostics, COPD, asthma, interstitial lung disease, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 4, 2019 Category: Pharmaceuticals Source Type: news

Nintedanib Slows Fibrosing Interstitial Lung Disease
MONDAY, Sept. 30, 2019 -- For patients with progressive fibrosing interstitial lung diseases, nintedanib is associated with a lower rate of decline in forced vital capacity (FVC) compared with placebo, according to a study published online Sept. 29... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 30, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves First Treatment, Ofev (Nintedanib), for ILD With Systemic Sclerosis, Scleroderma
MONDAY, Sept. 9, 2019 -- The U.S. Food and Drug Administration granted the first approval for a drug to slow the decline of pulmonary function in interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD), the agency... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 9, 2019 Category: General Medicine Source Type: news

FDA OKs Nintedanib (Ofev) for Rare Lung Disease FDA OKs Nintedanib (Ofev) for Rare Lung Disease
Nintedanib capsules are approved for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease.News Alerts (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 9, 2019 Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news

FDA approves first treatment for patients with rare type of lung disease
The U.S. Food and Drug Administration has approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma, called SSc-ILD. It is the first FDA-approved treatment for this rare lung condition. (Source: World Pharma News)
Source: World Pharma News - September 9, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Ofev (nintedanib) for Interstitial Lung Disease Associated with Systemic Sclerosis or Scleroderma (SSc-ILD)
September 06, 2019 -- The U.S. Food and Drug Administration today approved Ofev (nintedanib) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma,... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 6, 2019 Category: Drugs & Pharmacology Source Type: news

Trump Signs 9/11 Victims Fund Extension
President Donald Trump on Monday signed legislation that will extend the September 11th Victim Compensation Fund until 2092. During the signing ceremony at the White House, Trump was surrounding by first responders, survivors and family members of several who died in the 2001 terrorist attack on the United States. The U.S. House of Representatives and the U.S Senate voted overwhelmingly last week to approve the legislation that will provide a lifetime of assistance for victims and their families. The extension will allow the fund, first established in 2001, to pay for past and future medical claims of those effected by the...
Source: Asbestos and Mesothelioma News - July 29, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA Panel Recommends Nintedanib for Rare Lung Disease FDA Panel Recommends Nintedanib for Rare Lung Disease
Small effect size for primary endpoint in systemic sclerosis-associated interstitial lung disease study, and lack of significant difference between groups for secondary outcomes, were sticking points.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - July 26, 2019 Category: Rheumatology Tags: Rheumatology News Source Type: news

9/11 Victims Fund Passes Senate
The Senate gallery erupted in applause from politicians and first responders on Tuesday after a 97-2 vote to extend the September 11 Victim Compensation Fund until 2092. The reauthorization will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension will allow victims and their families to file claims through 2090, but they will be paid out through 2092. The extension of funding will benefit victims who may develop mesothelioma linked to ...
Source: Asbestos and Mesothelioma News - July 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Senate Passes 9/11 Victim Compensation Fund Extension
The U.S. Senate followed the House of Representatives on Tuesday and passed legislation that will extend the September 11 Victim Compensation Fund until 2092. The legislation will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension of funding will benefit victims who may develop mesothelioma linked to the more than 400 tons of asbestos that covered the 16-acre disaster zone after the twin towers fell. According to World Trade Center R...
Source: Asbestos and Mesothelioma News - July 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

A Pro-Con Debate on How to Care for Patients With Interstitial Lung Disease
DALLAS--Which patients are candidates for antifibrotic therapy? Is extracorporeal membrane oxygenation appropriate for all ILD patients? The topics were hotly debated on Monday at the American Thoracic Society meeting.   (Source: ConsultantLive)
Source: ConsultantLive - May 21, 2019 Category: Internal Medicine Authors: Christina Bennett, MS Tags: Conferences/ATS Source Type: news

nintedanib slows pulmonary function loss in people with ssc-ild
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD1Results of pivotal Phase III SENSCIS ®trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USAInterstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) – also known as scleroderma – and the absence of approved treatment options constitutes a high unmet need2,3FDA grants priority review to application for regulatory approval for nintedanib in patients ...
Source: Boehringer Ingelheim Corporate News - May 20, 2019 Category: Research Source Type: news

Pembrokeshire girl, 10, dies waiting for lung transplant
Belle Curran won numerous bravery awards as she battled with rare Interstitial Lung Disease. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 7, 2019 Category: Consumer Health News Source Type: news

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib as an anti-fibrotic medicine is already approved in more than 70 countries for the treatment of patients living with idiopathic pulmonary fibrosis (IPF). (Source: World Pharma News)
Source: World Pharma News - March 26, 2019 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Systemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue disease Pulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need ... Biopharmaceuticals, FDA, Regulatory Boehringer Ingelheim, nintedanib, interstitial lung disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2019 Category: Pharmaceuticals Source Type: news

FDA-and-EMA-regulatory-submission-nintedanib-in-SSc-ILD
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILDSystemic sclerosis (SSc), also known as scleroderma, is a rare chronic connective tissue diseasePulmonary fibrosis, or fibrosing interstitial lung disease (ILD), is a key driver of mortality in people living with SSc and constitutes a high unmet need1,2Improving the lives of people living with pulmonary fibrosis is a key focus for Boehringer Ingelheim (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 15, 2019 Category: Research Source Type: news

Complex Dosing, Polypharmacy Common With Interstitial Lung Disease
Patients receiving systemic corticosteroids are at high risk for drug - disease interactions (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 14, 2019 Category: Respiratory Medicine Tags: Pharmacy, Pulmonology, Journal, Source Type: news

Complex Dosing, Polypharmacy Common With Interstitial Lung Disease
THURSDAY, March 14, 2019 -- Polypharmacy and complex medication regimens are common in patients with interstitial lung disease (ILD), according to a study published online Feb. 20 in Respirology. Yet H. Khor, M.B.B.S., Ph.D., from the University of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 14, 2019 Category: Pharmaceuticals Source Type: news